RedHill Biopharma (RDHL) Tops Q2 EPS by 52c, Beats on Revenues

RedHill Biopharma (NASDAQ: RDHL) reported Q2 EPS of ($0.06), $0.52 better than the analyst estimate of ($0.58). Revenue for the quarter came in at $483 thousand versus the consensus estimate of $220 thousand.

For earnings history and earnings-related data on RedHill Biopharma (RDHL) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• AeroVironment (AVAV) Tops Q4 EPS by 36c
• AI chip winners may face tougher road ahead as hyperscalers catch up: JPM